8-K 1 a06-20192_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported)   September 25, 2006

Cephalon, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

 

0-19119

 

23-2484489

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification No.)

 

41 Moores Road

 

 

Frazer, Pennsylvania

 

19355

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code   (610) 344-0200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 8.01               Other Events.

On September 25, 2006, Cephalon, Inc. (the “Company”) issued a press release regarding the United States Food and Drug Administration’s approval of FENTORA™ (fentanyl buccal tablet) [C-II] for the treatment of breakthrough pain in patients with cancer.   The Company hereby incorporates by reference the press release dated September 25, 2006, attached hereto as Exhibit 99.1, and made a part of this Item 8.01.

Item 9.01               Financial Statements and Exhibits.

(d)

Exhibits

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number

 

 

 

Description

 

 

 

99.1

 

Press Release dated September 25, 2006

 



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CEPHALON, INC.

 

 

 

 

Date: September 25, 2006

By:

/s/ J. Kevin Buchi

 

 

 

J. Kevin Buchi

 

 

Executive Vice President and Chief Financial Officer

 

 



 

EXHIBIT INDEX

Exhibit

 

 

Number

 

 

 

Description

 

 

99.1

 

Press Release dated September 25, 2006